ElevateBio
PrivateLast Round
Series D
May 24, 2023
Total Funding Raised
$1.25B
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ElevateBio is a biotechnology company that provides an integrated platform for the discovery, development, and manufacturing of cell and gene therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ElevateBio Comparables
Compare ElevateBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| RoslinCT | 85% | |
| Resilience | 83% | |
| GeneFab | 81% |
For institutional investors. Book with your work email.
ElevateBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 24, 2023 | ||||
| Series C | Mar 15, 2021 | ||||
| Series B | Mar 30, 2020 | ||||
| Series A | May 13, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ElevateBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B, Series A, Series D, Series C |
| Redmile Group | Series B, Series A, Series D, Series C |
| MPM Capital | Series B, Series D, Series C, Series A |
| SoftBank Investment Advisers | Series D, Series C |
| Fidelity Management & Research Company | Series D, Series C |
| MPM BioImpact | Series A, Series B, Series D, Series C |
| SoftBank Group | Series D, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 51% MoM.
- Jan 5, 2026
Christopher Murphy named Chief Executive Officer and Board member.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 20, 2026
ElevateBio partners with MassBio to host 2026 R&D Reimagined - Techbio Solutions, the second in a series connecting biotech and pharma R&D leaders with technology innovators and solution providers, on Nov 2nd '26.
- hiresSep 1, 2026
On Sep 1st '26, ElevateBio appoints Steven Falcone as Chief Operating Officer to oversee operations and quality at its manufacturing and testing sites in Massachusetts and Pennsylvania.
- hiresSep 1, 2026
ElevateBio appoints Steven Falcone as Chief Operating Officer on Sep 1st '26 in Massachusetts, with responsibility for operations and quality, including compliant manufacturing and testing across its Waltham and Pittsburgh sites.
- expands_facilitiesSep 1, 2026
On Sep 1st '26, ElevateBio expands into a new site in Pittsburgh while readying its Waltham site for its first commercial product.
For institutional investors. Book with your work email.
ElevateBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ElevateBio's valuation, stock price, and market status.
Is ElevateBio a public or private company?
ElevateBio is a private company.
What is the current stock price of ElevateBio?
ElevateBio is a private company, so its shares have no public market price. Caplight tracks ElevateBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ElevateBio worth (valuation)?
Valuation information for ElevateBio is not publicly available.
Can I buy ElevateBio stock?
ElevateBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ElevateBio's last funding round?
ElevateBio's most recent funding round was Series D on May 24, 2023.
Who are the main investors in ElevateBio?
Key investors in ElevateBio include MPM Capital, MPM BioImpact, EDBI, Invus Opportunities, Matrix Capital Management.
Will ElevateBio IPO soon?
No public IPO plans have been announced for ElevateBio.
How can I track ElevateBio secondary market activity?
Caplight tracks bids, offers, and trades in ElevateBio's shares on secondary markets.